MannKind developing ralinepag dry powder inhalation (MNKD-1501) for United Therapeutics, receives $5M payment, eligible for up to $35M milestones plus 10% royalties
- Earnings scheduled today after market close; analysts expect non-GAAP EPS $0.00 and revenue $105.4M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.